This suggestion is based to the somewhat intensive literature describing the lower rates of adverse effects and pharmacokinetic stability leading to constructive clinical outcomes. [123]Biktarvy - bictegravir/tenofovir AF/emtricitabine — only for people with pretreatment estimated CrCl ≥30 m